Publications by authors named "R G Annett"
Introduction: Understanding caregiver willingness to participate in pediatric clinical research is needed. We examined caregiver perceptions of pediatric clinical research during COVID-19 and examined research attitudes and sociodemographic factors as predictors of willingness.
Methods: A cross-sectional telephone survey was administered to caregivers of children from August 2020 to April 2021.
Article Synopsis
- Researchers need to find out what factors might put babies at risk of being taken out of their homes, especially due to their parents' substance use.
- In a study with 1,808 parent-baby pairs, most of the parents were Non-Hispanic White, and many babies were exposed to drugs like alcohol and opioids before birth.
- The study found that many babies with drug exposure didn't get to go home with their parents, and understanding how substance use affects placement decisions can help improve support for families in need.
Article Synopsis
- The BIOFIRE Joint Infection (JI) Panel uses multiplex-PCR testing to identify microorganisms in synovial fluid from patients suspected of septic arthritis and prosthetic joint infections.
- A study over 34 clinical sites in Europe and the Middle East indicated that the JI Panel showed 88.4% agreement in diagnosing septic arthritis and 85% for prosthetic joint infections when compared to traditional synovial fluid cultures.
- The JI Panel not only detected more positive samples, especially anaerobic bacteria, but also provided results in about one hour, improving patient management and treatment decisions.
Background: Acute viral bronchiolitis is the most common reason for hospitalization of infants in the USA. Infants hospitalized for bronchiolitis are at high risk for recurrent respiratory symptoms and wheeze in the subsequent year, and longer-term adverse respiratory outcomes such as persistent childhood asthma. There are no effective secondary prevention strategies.
View Article and Find Full Text PDFArticle Synopsis
- Defining prognostic factors for T-lymphoblastic lymphoma (T-LL) is complex, as shown in the AALL1231 trial that included children and young adults with T acute lymphoblastic leukemia or T-LL, comparing standard therapy with the addition of bortezomib.
- In the trial, 41% of patients provided bone marrow samples to measure minimal residual disease (MRD) after treatment, revealing that those with MRD levels below 0.1% had a significantly better event-free survival rate (89%) compared to those with MRD at or above 0.1% (64%).
- Cox regression analysis indicated that having MRD levels at or above 0.1%